Generex Biotechnology Corporation
(Public, NASDAQ: GNBT)
This past year, small cap biotech investors were witness to some of the most profitable gains ever recorded. The only way to encapsulate it would be through two simple words, “FDA Approval”. Yes, any company with high probability of approval on their blockbuster drugs saw their shares literally explode beyond technical [...]
